Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.42
-5.45 (-3.87%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
51
52
Next >
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
January 22, 2024
Via
Benzinga
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money
January 22, 2024
Healthcare is nearly a fifth of America's economy. Ride these high-flying healthcare stocks to monster gains.
Via
The Motley Fool
Topics
Economy
Exposures
Economy
3 High-Flying Stocks That Could Soar Even More in 2024
January 20, 2024
These big winners could keep the momentum going.
Via
The Motley Fool
Weightloss Drugs Ozempic And Wegovy's Success Sets Novo Nordisk's Owner To Utilize Dividend Windfall For Strategic Investments
January 19, 2024
Explore Novo Holdings' 2024 plans for acquisitions and investments in Asia, led by CEO Kasim Kutay. Discover strategic initiatives, global studies on NVO drugs, and insights into challenges and...
Via
Benzinga
Is Novo Nordisk Stock a Buy Now?
January 18, 2024
The biotech is on a roll, and that won't end soon.
Via
The Motley Fool
Check Out What Whales Are Doing With NVO
January 17, 2024
Via
Benzinga
Why Novo Nordisk Stock Soared 53% in 2023 (Hint: It Wasn't Just Ozempic)
January 13, 2024
Last year was one for the history books for the Danish drugmaker.
Via
The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today
January 12, 2024
Via
Benzinga
P/E Ratio Insights for Novo Nordisk
January 11, 2024
Via
Benzinga
These 2 Top Healthcare Stocks Declared Dividend Raises in 2023
January 15, 2024
For different reasons, both Eli Lilly and UnitedHealth are doing well enough to enact substantial dividend raises.
Via
The Motley Fool
Move Over, Novo Nordisk -- This Is the Pharmaceutical Company I am Most Bullish On in 2024
January 14, 2024
Novo Nordisk may dominate the weight management space, but pharma giant Eli Lilly is quickly gaining steam.
Via
The Motley Fool
After Surging 53% in 2023, This Pharmaceutical Stock Might Be About to Crash. Here's Why I'm Probably Wrong
January 13, 2024
The rise of Ozempic and Wegovy helped Novo Nordisk stock surge over 50% last year.
Via
The Motley Fool
3 Unstoppable Stocks to Buy in 2024
January 13, 2024
These stocks appear to be on a clear path to continued growth.
Via
The Motley Fool
Why WW International Stock Plummeted by 9% Today
January 11, 2024
The beleaguered company suffers another share price hit with a somewhat gloomy analyst update.
Via
The Motley Fool
FDA Finds No Evidence Weight-Loss Drugs Cause Suicidal Thoughts
January 11, 2024
The FDA released an update on Thursday stating that its preliminary review did not find definitive evidence that the drugs cause suicidal thoughts or actions. However, the FDA investigation will...
Via
Benzinga
Exposures
Product Safety
Looking At Novo Nordisk's Recent Unusual Options Activity
January 10, 2024
Via
Benzinga
Could Novo Nordisk Stock Help You Retire a Millionaire?
January 08, 2024
This company is steadily gaining in value, and its growth runway is quite long, too.
Via
The Motley Fool
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
Pfizer’s 2024 Outlook: Is PFE Stock Poised for a Major Rebound?
January 11, 2024
Pfizer is certainly a company that will need to continue to battle headwinds moving forward, but is PFE stock worth a buy?
Via
InvestorPlace
Why Eli Lilly Stock Skyrocketed 59% in 2023
January 11, 2024
Lilly's pipeline success in 2023 allowed it to to claim the crown as the biggest drugmaker on the planet by market cap.
Via
The Motley Fool
Bullish Continuation In '24? 3 Market Areas To Watch
January 10, 2024
This article discusses 3 market areas that should outperform dramatically over the next 12 months...
Via
Talk Markets
Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments
January 10, 2024
Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million.
Via
Benzinga
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
January 05, 2024
Via
Benzinga
Bring On The Competition In Obesity Drugs: Novo Nordisk CEO Optimistic About Prolonged Patient Adherence to Obesity Drug Wegovy
January 10, 2024
Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S (NYSE: NVO), shared insights during the JPMorgan Healthcare conference, highlighting Wegovy's efficacy for weight loss, indicating that patients are...
Via
Benzinga
3 Simple Tricks That Every Investor Should Use (but Most Don't)
January 09, 2024
Having a few tricks up your sleeve can increase your returns over time.
Via
The Motley Fool
Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles
January 09, 2024
Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning
Via
Benzinga
Ozempic Users Might Experience Caloric Intake Rise Post-Discontinuation: Survey
January 08, 2024
Novo Nordisk's Wegovy has been linked to greater weight loss with prolonged use, with 40% of patients still using the drug a year later. This adherence rate is three times higher than other...
Via
Benzinga
Dexcom's Recent 66% Run Continues With A Breakout On Bullish Fourth-Quarter Sales
January 08, 2024
Dexcom beat fourth-quarter sales expectations and issued stronger-than-usual annual guidance.
Via
Investor's Business Daily
Wegovy and Ozempic Maker Novo Nordisk Shares Data From Phase 3 Diabetes Study Of Semaglutide/Insulin Containing Candidate
January 08, 2024
Novo Nordisk A/S (NYSE: NVO) announced topli
Via
Benzinga
Nvidia, Spotify Lead Five Stocks Near Buy Points
January 06, 2024
Nvidia could make some noise with its CES presentation Monday.
Via
Investor's Business Daily
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.